Trademark Overview
On Thursday, March 12, 2026, a trademark application was filed for PROGRAMMING CANCER with the United States Patent and Trademark Office. The USPTO has given the PROGRAMMING CANCER trademark a serial number of 99699099. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Sunday, June 28, 2026. This trademark is owned by Earli Inc.. The PROGRAMMING CANCER trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:
Products for the prevention of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the localization of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for localization of cancer; Products for the therapy of cancer in humans, namely, pharmaceutical products to express a treatment agent for treating cancer; Products for the prevention of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the therapy of cancer in animals, namely, pharmaceutical products to express a treatment agent for treating cancer
Medical services for the prevention of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the localization of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for the localization of cancer; Medical services for the therapy of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for treating cancer; Medical services for the prevention of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in animals, namely, medical assay processing provided by medical labo...
